Discover
CRBP
Corbus Pharmaceuticals Holdings, Inc.
9.07
1 x 8.80
1 x 10.44
bid
ask
-
0.31
3.30%
1 @ 07:36 AM
9.03 -0.04 (0.44%)
| Ytd | 11.43% | |
| 1y | 26.68% |
8.99
day range
9.45
7.12
52 week range
20.56
| Open | 9.29 | Prev Close | 9.38 | Low | 8.99 | High | 9.45 | Mkt Cap | 168.05M |
| Vol | 441.38K | Avg Vol | 489.57K | EPS | -5.74 | P/E | N/A | Forward P/E | -2.51 |
| Beta | 2.56 | Short Ratio | 8.28 | Inst. Own | 105.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 9.29 | 200-d Avg | 10.19 | 1yr Est | 56.78 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.99 | -1.15 | -0.16 | -16.16% |
| 2024-08-06 | 2024-06 | -1.16 | -0.9 | 0.26 | 22.41% |
| 2024-05-07 | 2024-03 | -1.09 | -0.83 | 0.26 | 23.85% |
| 2024-03-12 | 2023-12 | -2.36 | -1.81 | 0.55 | 23.31% |
| 2023-11-07 | 2023-09 | -2.06 | -2.27 | -0.21 | -10.19% |
| 2023-08-08 | 2023-06 | -3.1 | -2.05 | 1.05 | 33.87% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-02 | Piper Sandler | Upgrade | Overweight | |
| 2024-08-07 | RBC Capital | Upgrade | Outperform | Outperform |
| 2024-08-07 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-08-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-10 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-06-26 | B. Riley Securities | Upgrade | Buy |
Profile
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-05-29 | ALTMEYER ANNE | Director | 2.78K | Stock Award(Grant) |
| 2024-05-29 | CATLIN AVERY W | Director | 4.35K | Stock Award(Grant) |
| 2024-06-17 | COHEN YUVAL | Chief Executive Officer | 77.22K | Sale |
| 2024-09-19 | CORMORANT ASSET MANAGEMENT ,L.P | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-06-13 | HOLMER ALAN F | Director | 5.83K | Conversion of Exercise of derivative security |
| 2024-05-29 | JACQUES RACHELLE SUZANNE | Director | 2.78K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Cormorant Asset Management, LP | 2.38M | 31.25M | 19.50% |
| 2024-09-29 | Octagon Capital Advisors LP | 1.12M | 14.67M | 9.15% |
| 2024-09-29 | Orbimed Advisors LLC. | 912.55K | 12.01M | 7.49% |
| 2024-09-29 | Blackrock Inc. | 802.72K | 10.56M | 6.59% |
| 2024-09-29 | Vanguard Group Inc | 645.65K | 8.50M | 5.30% |
| 2024-09-29 | Tang Capital Management, LLC | 600.00K | 7.90M | 4.93% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 391.28K | 5.15M | 3.21% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 329.22K | 4.33M | 2.70% |
| 2024-10-30 | iShares Russell 2000 ETF | 269.24K | 3.54M | 2.21% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 169.06K | 2.22M | 1.39% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 104.06K | 1.37M | 0.85% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 68.25K | 898.22K | 0.56% |
Split
| Split | Date |
|---|---|
| 1 : 30 | 2023-02-14 |